Adalimumab
Arthritis, Psoriatic
Arthritis, Rheumatoid
Colitis, Ulcerative
Spondylitis, Ankylosing

Adalimumab

Adalimumab is a fully human, recombinant monoclonal antibody with high affinity and was the third tumor necrosis factor-alpha (TNF- ) inhibitor. Adalimumab is used to treat various autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis. The original adalimumab molecule received its initial approval from the U.S. Food and Drug Administration (FDA) for treating rheumatoid arthritis. This activity comprehensively reviews the indications, mechanism of action, administration, potential adverse effects, and contraindications of adalimumab, providing the interprofessional healthcare team with the necessary information to effectively utilize the drug and treat certain autoimmune conditions. This topic also emphasizes the warnings, precautions, and potential drug-drug interactions associated with adalimumab when administered to patients with autoimmune disorders.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.